Compare EME & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EME | NTRA |
|---|---|---|
| Founded | 1987 | 2003 |
| Country | United States | United States |
| Employees | 25000 | N/A |
| Industry | Engineering & Construction | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.2B | 28.0B |
| IPO Year | 1994 | 2015 |
| Metric | EME | NTRA |
|---|---|---|
| Price | $741.72 | $197.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | ★ $831.67 | $259.07 |
| AVG Volume (30 Days) | 338.5K | ★ 1.1M |
| Earning Date | 06-01-2026 | 05-19-2026 |
| Dividend Yield | ★ 0.22% | N/A |
| EPS Growth | ★ 30.99 | 0.65 |
| EPS | ★ 28.19 | N/A |
| Revenue | ★ $16,986,422,000.00 | $210,939,000.00 |
| Revenue This Year | $7.48 | $16.65 |
| Revenue Next Year | $7.51 | $19.22 |
| P/E Ratio | $25.82 | ★ N/A |
| Revenue Growth | ★ 16.62 | N/A |
| 52 Week Low | $320.89 | $125.38 |
| 52 Week High | $835.00 | $256.36 |
| Indicator | EME | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 52.11 | 42.97 |
| Support Level | $600.37 | $194.03 |
| Resistance Level | $747.78 | $251.09 |
| Average True Range (ATR) | 21.46 | 8.27 |
| MACD | -2.51 | 0.24 |
| Stochastic Oscillator | 83.49 | 41.23 |
EMCOR Group Inc is a specialty contractor in the United States and a provider of electrical and mechanical construction and facilities services, building services, and industrial services. Its services are provided to a broad range of commercial, technology, manufacturing, industrial, healthcare, utility, and institutional customers through approximately 100 operating subsidiaries. The company's operating subsidiaries are organized into reportable segments: United States mechanical construction and facilities services, which derives key revenue; United States electrical construction and facilities services; United States building services; United States industrial services; and United Kingdom building services. Geographically, its key revenue is derived from the United States.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.